Form 4: GALT Director Sells Shares After Option Exercise

Galectin Therapeutics Director Harold H. Shlevin exercised stock options and subsequently sold a portion of his common stock holdings on December 17, 2025, under a pre-arranged 10b5-1 plan.

Summary

• Harold H. Shlevin, a Director of Galectin Therapeutics Inc. (GALT), reported transactions on December 17, 2025.
• He exercised stock options to acquire 20,000 shares of common stock at an exercise price of $1.98 per share.
• Following the exercise, he sold 19,793 shares of common stock at a weighted average price of $7.038 per share.
• Additionally, he sold another 4,706 shares of common stock at a weighted average price of $7.038 per share.
• All transactions were conducted pursuant to a Rule 10b5-1 plan adopted on August 29, 2025.
• The options vested 100% on December 31, 2022.
• After these transactions, Shlevin's direct beneficial ownership of common stock is 6,500 shares.

Sentiment

Score: 6

Explanation: The director realized a significant profit from exercising options at a low price and selling at a higher price. The use of a Rule 10b5-1 plan indicates the transaction was pre-scheduled and not based on immediate non-public information, which is a positive for corporate governance. However, any insider selling can be viewed with slight caution by the market.

Positives

• The sale price of $7.038 per share is significantly higher than the exercise price of $1.98 per share, indicating a profitable transaction for the director.
• The transactions were conducted under a pre-arranged Rule 10b5-1 plan, which suggests the sales were not based on new, non-public information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces the director's direct stake in the company.

Risks

• Potential negative investor sentiment if the market interprets the insider selling as a lack of confidence, despite the 10b5-1 plan.

Future Outlook

NA

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are common in the public markets. These plans allow insiders to pre-arrange sales or purchases of company stock to avoid accusations of trading on material non-public information. While the sale itself is a reduction in insider holdings, the existence of a 10b5-1 plan often mitigates concerns about opportunistic selling.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the director's profitable sale positively as a sign of value realization, but also potentially with caution as a reduction in insider ownership. The 10b5-1 plan provides reassurance regarding the timing of the sale.

Key Dates

Keywords

Galectin Therapeutics, GALT, Form 4, Insider Trading, Stock Options, Director, Share Sale, 10b5-1 Plan, Equity Transaction, Beneficial Ownership